Anterior|Siguiente

Mecanismo de Wumei Wan para inhibir el cáncer colorrectal metastásico mediante la promoción de la polarización de macrófagos tumorales M1

  • role： First author第一作者
  • Affiliation：

    Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine（TCM），Shanghai 201203，China

  • Email：saber930607@163.com
  • Introduction：陈念芝，博士，从事中医药防治恶性肿瘤研究，E-mail： saber930607@163.com
CHEN Nianzhi1,  
  • Affiliation：

    Affiliated Hospital of Chengdu University of TCM，Chengdu 610075，China

TANG Shiyun2,  
  • Affiliation：

    Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine（TCM），Shanghai 201203，China

FENG Yuanyuan1,  
  • Affiliation：

    Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine（TCM），Shanghai 201203，China

WANG Yan1,  
  • role： Corresponding author通信作者
  • Affiliation：

    Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine（TCM），Shanghai 201203，China

  • Email：liuningning689@126.com
  • Introduction：刘宁宁，博士，副主任医师，副教授，硕士生导师，从事中医药防治消化道恶性肿瘤研究，E-mail：liuningning689@126.com
LIU Ningning1*

resumen

El objetivo es explorar el efecto de la fórmula Wumei Wan en el proceso de metástasis hepática y pulmonar del cáncer colorrectal metastásico, así como sus posibles mecanismos de acción. Métodos: los ratones se dividieron aleatoriamente en grupo control, grupos de baja y alta dosis de Wumei Wan (20, 40 g·kg⁻¹) y grupo de paclitaxel (0.01 g·kg⁻¹), luego se estableció un modelo de metástasis hepática y pulmonar de cáncer colorrectal en ratones. La intervención con medicamentos duró 4 semanas, registrando el peso corporal, peso del hígado y pulmón, y la supervivencia. Se usó tinción con hematoxilina y eosina (HE) para evaluar el efecto de Wumei Wan en las metástasis. La PCR en tiempo real evaluó los niveles de ARNm de marcadores de macrófagos M1 y M2 en tejidos hepáticos y pulmonares. La citometría de flujo midió los marcadores de macrófagos M1 CD80 y CD86. Resultados: en el modelo, comparado con el control, los grupos de Wumei Wan y paclitaxel mostraron disminución significativa en peso corporal y peso hepático/pulmonar (P<0.01) y aumento significativo en la supervivencia (P<0.01). La histopatología mostró inhibición de las metástasis. La PCR mostró aumento significativo de marcadores M1 (IL-1β, IL-6, TNF-α, iNOS, PTGS2) y disminución de marcadores M2 (Arg1, CD163, CD206) (P<0.01). La citometría mostró incremento en CD86 y CD80 (P<0.01). La inmunohistoquímica indicó aumento en expresión de CD86 e inhibición de CD206. Conclusión: Wumei Wan inhibe las metástasis hepáticas y pulmonares del cáncer colorrectal al promover la polarización de macrófagos M1 asociados al tumor.

palabra clave

Wumei Wan;cáncer colorrectal;metástasis hepáticas;metástasis pulmonares;macrófagos

References

  1. 1.
    PATEL S G，KARLITZ J J，YEN T，et al.The rising tide of early-onset colorectal cancer： A comprehensive review of epidemiology，clinical features，biology，risk factors，prevention，and early detection［J］.Lancet Gastroenterol Hepatol，2022，7（3）：262-274.
  2. 2.
    LI R，LIU X F，HUANG X D，et al.Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis［J］.Gut，2024，73（3）：470-484.
  3. 3.
    BERTOCCHI A，CARLONI S，RAVENDA P S，et al.Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver［J］.Cancer Cell，2021，39（5）：708-724.e11.
  4. 4.
    HUANG Y W，ZHAO M N，YIN J C，et al.Pulmonary metastasis in newly diagnosed colon-rectal cancer： A population-based nomogram study［J］.Int J Colorectal Dis，2019，34（5）：867-878.
  5. 5.
    CAI Y M，ZHANG X Q，ZHAO G L，et al.Mechanism of small molecules of traditional Chinese medicine targeting tumor-associated macrophages in gastrointestinal tumors：A review ［J］.Chin J Exp Tradit Med Form，2024，30（21）：271-278.
  6. 6.
    HAO X P，ZHENG Z Y，LIU H Y，et al.Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing［J］.Redox Biol，2022，56：102463.
  7. 7.
    GUO M Z，YANG X Q，YANG Y Y，et al.Treatment of colorectal cancer on account of Jueyin［J］.J Pract Tradit Chin Intern Med，2020，34（11）：10-13.
  8. 8.
    ZHAO H F.The effect and mechanism of Wumei pill in colorectal cancer based PD-L1/PD-1 pathway［D］.Tianjin：Tianjin Univ Tradit Chin Med，2023.
  9. 9.
    DOU C W，LIU Z K，TU K S，et al.P300 acetyltransferase mediates stiffness-induced activation of hepatic stellate cells into tumor-promoting myofibroblasts［J］.Gastroenterology，2018，154（8）：2209-2221.
  10. 10.
    CHEN F M，LI T L，ZHANG H J，et al.Acid-ionizable iron nanoadjuvant augments STING activation for personalized vaccination immunotherapy of cancer［J］.Adv Mater，2023，35（10）：e2209910.
  11. 11.
    WANG P，LI J C，REN M L，et al.Effects of Wumei pill on gene microenvironment expression profile and immune-related gene expression in orthotopic tumor of breast cancer mice［J］.China J Tradit Chin Med Pharm，2024，39（2）：913-920.
  12. 12.
    LI Q，MA Z，LIU Y H，et al.Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model［J］.FEBS J，2016，283（15）：2836-2852.
  13. 13.
    Shanghai Anti-Cancer Association Colorectal Cancer Committee.Shanghai plan for early screening，diagnosis and treatment of colorectal cancer（2023 edition）［J］.Chin J Cancer，2024，34（1）：13-66.
  14. 14.
    ZHU D X，REN L，XU J M.Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases（2023 edition）［J］.Chin J Gen Surg，2023，32（1）：1-29.
  15. 15.
    TRAN E，ROBBINS P F，LU Y C，et al.T-cell transfer therapy targeting mutant KRAS in cancer［J］.N Engl J Med，2016，375（23）：2255-2262.
  16. 16.
    JIANG Z C，ZHANG W，ZHOU A P.Research progress on triplet chemotherapy for advanced colorectal cancer［J］.Chin J Clin Oncol，2021，48（4）：201-205.
  17. 17.
    WEI X M，LI L，CHENG H B.Discuss on the pathogenesis of colorectal precancerous from the perspective of traditional Chinese medicine［J］.J Nanjing Univ Chin Med，2021，37（3）：348-351.
  18. 18.
    LI J，WANG Z W，DENG J，et al.Discussion on feasibility of Wumei pill in the treatment of colorectal cancer［J］.World Chin Med，2023，18（8）：1178-1182.
  19. 19.
    CHEN H B，LIN C Z.Wumei pill in treatment of diseases of large intestine： A review［J］.Chin J Exp Tradit Med Form，2023，29（1）：250-257.
  20. 20.
    ZHANG R，LI S J，CHEN Z Y，et al.Mechanism exploration of modified Wumei pill on colon cancer inhibition via Wnt pathways［J］.World Chin Med，2018，13（8）：1972-1975.
  21. 21.
    CHRISTOFIDES A，STRAUSS L，YEO A，et al.The complex role of tumor-infiltrating macrophages［J］.Nat Immunol，2022，23（8）：1148-1156.
  22. 22.
    MANTOVANI A，ALLAVENA P，MARCHESI F，et al.Macrophages as tools and targets in cancer therapy［J］.Nat Rev Drug Discov，2022，21（11）：799-820.
  23. 23.
    CHEN S Z，SAEED A F U H，LIU Q，et al.Macrophages in immunoregulation and therapeutics［J］.Sig Transduct Target Ther，2023，8（1）：207.
  24. 24.
    LOCATI M，CURTALE G，MANTOVANI A. Diversity，mechanisms， and significance of macrophage plasticity［J］.Annu Rev Pathol，2020，15（1）：123-147.
  25. 25.
    GUO M X，LIN Y X，CAI M Y，et al.Traditional Chinese medicine regulates tumor-associated macrophages in colorectal cancer：A review［J］.Chin J Exp Tradit Med Form，2024，30（22）：279-288.
  26. 26.
    MANTOVANI A，MARCHESI F， MALESCI A，et al.Tumour-associated macrophages as treatment targets in oncology［J］.Nat Rev Clin Oncol，2017，14（7）：399-416.
  27. 27.
    LI H，XIAO Y，LI Q，et al.The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1［J］.Cancer cell，2022，40（1）：36-52.
  28. 28.
    KUMAR S.Cellular and molecular pathways of renal repair after acute kidney injury［J］.Kidney Int，2018，93（1）：27-40.
  29. 29.
    WYNN T A，CHAWLA A，POLLARD J W.Macrophage biology in development，homeostasis and disease［J］.Nature，2013，496（7446）：445-455.
  30. 30.
    QIAO Y Y，FU E Q.Advances in the study of tumor-associated macrophages in lung cancer ［J］.Chin J Lung Cancer，2022，25（1）：34-39.
  31. 31.
    GUNASSEKARAN G R，POONGKAVITHAI VADEVOO S M，BAEK M C，et al.M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages［J］.Biomaterials，2021，278：121137.

Leer el texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website